Table 3.
Antiserum | Synthetic peptide used for immunisation (amino acid sequence) | EBOVa | SUDV | TAFV | BDBV | RESTV | MARV |
---|---|---|---|---|---|---|---|
FS0169 | EBOV NP 628-638 (QDHTQEARNQD) | ++b | − | ||||
FS0191 | SUDV NP 631-644 (QGSESEALPINSKK) | − | ++ | − | − | − | − |
FS0046 | TAFV NP 630-643 (NQVSGSENTDNKPH) | − | − | ++ | − | + | − |
FS0048 | BDBV NP 628-641 (QSNQTNNEDNVRNN) | − | − | − | ++ | + | − |
FS0170 | RESTV NP 630-643 (TSQLNEDPDIGQSK) | − | − | − | − | + | − |
FS0610 | MARV NP 635-652 (RVVTKKGRTFLYPNDLLQ) | − | − | − | − | − | ++ |
VLPs of each virus species were used as antigens.
Antibody reactivity was evaluated based on ELISA OD450 values at a serum dilution of 1:2000. ++, OD> 1.0; +, 0.5<OD<1; −, OD<0.5.